- Home
- CRVS vs EBS Comparison
CRVS vs EBS Comparison
Compare CRVS & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- EBS
- Stock Information
- Founded
- CRVS 2014
- EBS 1998
- Country
- CRVS United States
- EBS United States
- Employees
- CRVS N/A
- EBS N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- EBS Health Care
- Exchange
- CRVS Nasdaq
- EBS Nasdaq
- Market Cap
- CRVS 516.0M
- EBS 518.0M
- IPO Year
- CRVS 2016
- EBS 2006
- Fundamental
- Price
- CRVS $5.22
- EBS $10.20
- Analyst Decision
- CRVS Strong Buy
- EBS Strong Buy
- Analyst Count
- CRVS 5
- EBS 3
- Target Price
- CRVS $12.38
- EBS $14.33
- AVG Volume (30 Days)
- CRVS 1.6M
- EBS 1.1M
- Earning Date
- CRVS 11-12-2024
- EBS 03-04-2025
- Dividend Yield
- CRVS N/A
- EBS N/A
- EPS Growth
- CRVS N/A
- EBS N/A
- EPS
- CRVS N/A
- EBS N/A
- Revenue
- CRVS N/A
- EBS $1,125,500,000.00
- Revenue This Year
- CRVS N/A
- EBS $6.26
- Revenue Next Year
- CRVS N/A
- EBS $2.42
- P/E Ratio
- CRVS N/A
- EBS N/A
- Revenue Growth
- CRVS N/A
- EBS 2.05
- 52 Week Low
- CRVS $1.30
- EBS $1.42
- 52 Week High
- CRVS $10.00
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- CRVS 41.23
- EBS 60.60
- Support Level
- CRVS $4.60
- EBS $9.20
- Resistance Level
- CRVS $6.47
- EBS $10.63
- Average True Range (ATR)
- CRVS 0.39
- EBS 0.67
- MACD
- CRVS 0.06
- EBS 0.05
- Stochastic Oscillator
- CRVS 33.16
- EBS 81.86
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.